A summary for those who missed the conference call, the board of...

A summary for those who missed the conference call, the board of ResApp were also listening in:

- Sanofi have not dropped Out! They simply did not exercise their option before the due date. They are still moving forward and highly engaged with ResApp, for them its about aligning certain internal stakeholders.
- Regarding the FDA Submission, ResApp believes their points can be addressed and best of all a resubmission can be made without conducting an additional clinical trial. This all depends on the outcome of the FDA meeting which will be in the next few months.
- Sleep Apnea Product coming out soon, CE file ready for submission end of this month
- Coviu integration is being finalised and a deal end of this month. Well into the Sales process with a number of other Telehealth providers in Europe and Australia.
- There are 750M People in Europe, More people in Europe than in the US where there is significant interest. NHS are making a Telehealth push by April 2021 same with Germany. Over 50% are respiratory-related consultations on Telehealth.
- COVID 19 ongoing discussion with government entities, ResApp-Dx could be used with better specificity and reduce overcrowding in hospitals. COVID 19 may have a unique cough signature in patients and ResApp are working to potentially collect this data.
- Balance sheet is robust

The biggest takeaway was that several milestones are imminent, and a significant market for ResApp exists to prove their worth on a portfolio of digital products. Sanofi are still engaged and the interest is only building with the current global pandemic underway.

2020 is the year ResApp will become a commercial entity.